- Home
- AIRS vs CLLS Comparison
AIRS vs CLLS Comparison
Compare AIRS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- CLLS
- Stock Information
- Founded
- AIRS 2012
- CLLS 1999
- Country
- AIRS United States
- CLLS France
- Employees
- AIRS N/A
- CLLS N/A
- Industry
- AIRS Medical/Nursing Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- CLLS Health Care
- Exchange
- AIRS Nasdaq
- CLLS Nasdaq
- Market Cap
- AIRS 400.5M
- CLLS 240.2M
- IPO Year
- AIRS 2021
- CLLS 2007
- Fundamental
- Price
- AIRS $5.35
- CLLS $1.57
- Analyst Decision
- AIRS Hold
- CLLS Buy
- Analyst Count
- AIRS 2
- CLLS 3
- Target Price
- AIRS $5.00
- CLLS $7.00
- AVG Volume (30 Days)
- AIRS 237.8K
- CLLS 56.7K
- Earning Date
- AIRS 11-08-2024
- CLLS 11-04-2024
- Dividend Yield
- AIRS N/A
- CLLS N/A
- EPS Growth
- AIRS N/A
- CLLS N/A
- EPS
- AIRS N/A
- CLLS N/A
- Revenue
- AIRS $188,780,000.00
- CLLS $36,042,000.00
- Revenue This Year
- AIRS N/A
- CLLS $271.02
- Revenue Next Year
- AIRS $10.31
- CLLS $33.48
- P/E Ratio
- AIRS N/A
- CLLS N/A
- Revenue Growth
- AIRS N/A
- CLLS 46.96
- 52 Week Low
- AIRS $2.92
- CLLS $1.53
- 52 Week High
- AIRS $9.20
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- AIRS 38.88
- CLLS 27.91
- Support Level
- AIRS $5.58
- CLLS $1.85
- Resistance Level
- AIRS $6.60
- CLLS $2.09
- Average True Range (ATR)
- AIRS 0.58
- CLLS 0.09
- MACD
- AIRS -0.15
- CLLS -0.04
- Stochastic Oscillator
- AIRS 0.43
- CLLS 0.00
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.